The influence of chlormadinone acetate on the total and free serum prostate specific antigen levels in men with benign prostatic hyperplasia

Jin Seon Cho, Kyung Seop Lee, Bup Wan Kim, Sae Woong Kim, Choung Soo Kim, Choong Hee Noh, Hyun Yul Rhew, Kwangsung Park, Dong Soo Park, Jae Shin Park, Jong Kwan Park, Ill Young Seo, Tae Hee Oh, Sang Eun Lee, Byungha Chung, Se Il Jung, Jae Il Jung, Hee Chang Jung, In Rae Cho, Chun Il Kim

Research output: Contribution to journalArticle

Abstract

Purpose: Chlormadinone acetate (CMA) therapy for benign prostatic hyperplasia (BPH) may lower the serum prostate specific antigen (PSA) level. However, little is known about the effect of CMA on the total or free serum PSA levels of PSA. Such information would be important since PSA testing is useful for prostate cancer screening. Thus, we prospectively studied the effect of CMA therapy on the total and free serum PSA levels. Materials and methods: The patients with lower urinary tract symptoms (LUTS) and BPH who were aged over 50 years were treated with 50mg CMA for 6 months. Men with a PSA level greater than 10ng/ml were excluded to reduce the likelihood of including cases of occult prostate cancer. Those with suspicious findings on the digital rectal examination and serum PSA testing were biopsied to rule out prostate cancer. α-blocking agents were permitted to treat the men with LUTS. Serum levels of the total and free PSA were measured at the study baseline and after approximately 3 and 6 months. The prostate volume (PV) was assessed by transrectal ultrasonography. Results: The analysis included 170 patients with a mean age of 67.9 years, a baseline PV of 47.3ml and a baseline total PSA of 4.1ng/ml. The total PSA levels declined from 4.1ng/ml at baseline to 2.0ng/ml after 6 months of treatment (50.7% decrease, p < 0.01). The mean percent free PSA (21% to 22% at baseline) was not significantly altered by CMA treatment. The PSA levels and PV at baseline did not affect the rate of decline of PSA. Conclusions: The total PSA serum levels decreased by an average of 50% during CMA therapy, but the percent free PSA did not change significantly. This information is potentially useful in the interpretation of the PSA data that's used for early detection of prostate cancer in the men receiving CMA.

Original languageEnglish
Pages (from-to)368-371
Number of pages4
JournalKorean Journal of Urology
Volume47
Issue number4
DOIs
Publication statusPublished - 2006 Jan 1

Fingerprint

Chlormadinone Acetate
Prostatic Hyperplasia
Prostate-Specific Antigen
Serum
Prostatic Neoplasms
Prostate
Lower Urinary Tract Symptoms
Early Detection of Cancer
Therapeutics
Digital Rectal Examination

All Science Journal Classification (ASJC) codes

  • Urology

Cite this

Cho, Jin Seon ; Lee, Kyung Seop ; Kim, Bup Wan ; Kim, Sae Woong ; Kim, Choung Soo ; Noh, Choong Hee ; Rhew, Hyun Yul ; Park, Kwangsung ; Park, Dong Soo ; Park, Jae Shin ; Park, Jong Kwan ; Seo, Ill Young ; Oh, Tae Hee ; Lee, Sang Eun ; Chung, Byungha ; Jung, Se Il ; Jung, Jae Il ; Jung, Hee Chang ; Cho, In Rae ; Kim, Chun Il. / The influence of chlormadinone acetate on the total and free serum prostate specific antigen levels in men with benign prostatic hyperplasia. In: Korean Journal of Urology. 2006 ; Vol. 47, No. 4. pp. 368-371.
@article{1f52eb3a08af4b1383994c3dcc26bf50,
title = "The influence of chlormadinone acetate on the total and free serum prostate specific antigen levels in men with benign prostatic hyperplasia",
abstract = "Purpose: Chlormadinone acetate (CMA) therapy for benign prostatic hyperplasia (BPH) may lower the serum prostate specific antigen (PSA) level. However, little is known about the effect of CMA on the total or free serum PSA levels of PSA. Such information would be important since PSA testing is useful for prostate cancer screening. Thus, we prospectively studied the effect of CMA therapy on the total and free serum PSA levels. Materials and methods: The patients with lower urinary tract symptoms (LUTS) and BPH who were aged over 50 years were treated with 50mg CMA for 6 months. Men with a PSA level greater than 10ng/ml were excluded to reduce the likelihood of including cases of occult prostate cancer. Those with suspicious findings on the digital rectal examination and serum PSA testing were biopsied to rule out prostate cancer. α-blocking agents were permitted to treat the men with LUTS. Serum levels of the total and free PSA were measured at the study baseline and after approximately 3 and 6 months. The prostate volume (PV) was assessed by transrectal ultrasonography. Results: The analysis included 170 patients with a mean age of 67.9 years, a baseline PV of 47.3ml and a baseline total PSA of 4.1ng/ml. The total PSA levels declined from 4.1ng/ml at baseline to 2.0ng/ml after 6 months of treatment (50.7{\%} decrease, p < 0.01). The mean percent free PSA (21{\%} to 22{\%} at baseline) was not significantly altered by CMA treatment. The PSA levels and PV at baseline did not affect the rate of decline of PSA. Conclusions: The total PSA serum levels decreased by an average of 50{\%} during CMA therapy, but the percent free PSA did not change significantly. This information is potentially useful in the interpretation of the PSA data that's used for early detection of prostate cancer in the men receiving CMA.",
author = "Cho, {Jin Seon} and Lee, {Kyung Seop} and Kim, {Bup Wan} and Kim, {Sae Woong} and Kim, {Choung Soo} and Noh, {Choong Hee} and Rhew, {Hyun Yul} and Kwangsung Park and Park, {Dong Soo} and Park, {Jae Shin} and Park, {Jong Kwan} and Seo, {Ill Young} and Oh, {Tae Hee} and Lee, {Sang Eun} and Byungha Chung and Jung, {Se Il} and Jung, {Jae Il} and Jung, {Hee Chang} and Cho, {In Rae} and Kim, {Chun Il}",
year = "2006",
month = "1",
day = "1",
doi = "10.4111/kju.2006.47.4.368",
language = "English",
volume = "47",
pages = "368--371",
journal = "Korean Journal of Urology",
issn = "2005-6737",
publisher = "Korean Urological Association",
number = "4",

}

Cho, JS, Lee, KS, Kim, BW, Kim, SW, Kim, CS, Noh, CH, Rhew, HY, Park, K, Park, DS, Park, JS, Park, JK, Seo, IY, Oh, TH, Lee, SE, Chung, B, Jung, SI, Jung, JI, Jung, HC, Cho, IR & Kim, CI 2006, 'The influence of chlormadinone acetate on the total and free serum prostate specific antigen levels in men with benign prostatic hyperplasia', Korean Journal of Urology, vol. 47, no. 4, pp. 368-371. https://doi.org/10.4111/kju.2006.47.4.368

The influence of chlormadinone acetate on the total and free serum prostate specific antigen levels in men with benign prostatic hyperplasia. / Cho, Jin Seon; Lee, Kyung Seop; Kim, Bup Wan; Kim, Sae Woong; Kim, Choung Soo; Noh, Choong Hee; Rhew, Hyun Yul; Park, Kwangsung; Park, Dong Soo; Park, Jae Shin; Park, Jong Kwan; Seo, Ill Young; Oh, Tae Hee; Lee, Sang Eun; Chung, Byungha; Jung, Se Il; Jung, Jae Il; Jung, Hee Chang; Cho, In Rae; Kim, Chun Il.

In: Korean Journal of Urology, Vol. 47, No. 4, 01.01.2006, p. 368-371.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The influence of chlormadinone acetate on the total and free serum prostate specific antigen levels in men with benign prostatic hyperplasia

AU - Cho, Jin Seon

AU - Lee, Kyung Seop

AU - Kim, Bup Wan

AU - Kim, Sae Woong

AU - Kim, Choung Soo

AU - Noh, Choong Hee

AU - Rhew, Hyun Yul

AU - Park, Kwangsung

AU - Park, Dong Soo

AU - Park, Jae Shin

AU - Park, Jong Kwan

AU - Seo, Ill Young

AU - Oh, Tae Hee

AU - Lee, Sang Eun

AU - Chung, Byungha

AU - Jung, Se Il

AU - Jung, Jae Il

AU - Jung, Hee Chang

AU - Cho, In Rae

AU - Kim, Chun Il

PY - 2006/1/1

Y1 - 2006/1/1

N2 - Purpose: Chlormadinone acetate (CMA) therapy for benign prostatic hyperplasia (BPH) may lower the serum prostate specific antigen (PSA) level. However, little is known about the effect of CMA on the total or free serum PSA levels of PSA. Such information would be important since PSA testing is useful for prostate cancer screening. Thus, we prospectively studied the effect of CMA therapy on the total and free serum PSA levels. Materials and methods: The patients with lower urinary tract symptoms (LUTS) and BPH who were aged over 50 years were treated with 50mg CMA for 6 months. Men with a PSA level greater than 10ng/ml were excluded to reduce the likelihood of including cases of occult prostate cancer. Those with suspicious findings on the digital rectal examination and serum PSA testing were biopsied to rule out prostate cancer. α-blocking agents were permitted to treat the men with LUTS. Serum levels of the total and free PSA were measured at the study baseline and after approximately 3 and 6 months. The prostate volume (PV) was assessed by transrectal ultrasonography. Results: The analysis included 170 patients with a mean age of 67.9 years, a baseline PV of 47.3ml and a baseline total PSA of 4.1ng/ml. The total PSA levels declined from 4.1ng/ml at baseline to 2.0ng/ml after 6 months of treatment (50.7% decrease, p < 0.01). The mean percent free PSA (21% to 22% at baseline) was not significantly altered by CMA treatment. The PSA levels and PV at baseline did not affect the rate of decline of PSA. Conclusions: The total PSA serum levels decreased by an average of 50% during CMA therapy, but the percent free PSA did not change significantly. This information is potentially useful in the interpretation of the PSA data that's used for early detection of prostate cancer in the men receiving CMA.

AB - Purpose: Chlormadinone acetate (CMA) therapy for benign prostatic hyperplasia (BPH) may lower the serum prostate specific antigen (PSA) level. However, little is known about the effect of CMA on the total or free serum PSA levels of PSA. Such information would be important since PSA testing is useful for prostate cancer screening. Thus, we prospectively studied the effect of CMA therapy on the total and free serum PSA levels. Materials and methods: The patients with lower urinary tract symptoms (LUTS) and BPH who were aged over 50 years were treated with 50mg CMA for 6 months. Men with a PSA level greater than 10ng/ml were excluded to reduce the likelihood of including cases of occult prostate cancer. Those with suspicious findings on the digital rectal examination and serum PSA testing were biopsied to rule out prostate cancer. α-blocking agents were permitted to treat the men with LUTS. Serum levels of the total and free PSA were measured at the study baseline and after approximately 3 and 6 months. The prostate volume (PV) was assessed by transrectal ultrasonography. Results: The analysis included 170 patients with a mean age of 67.9 years, a baseline PV of 47.3ml and a baseline total PSA of 4.1ng/ml. The total PSA levels declined from 4.1ng/ml at baseline to 2.0ng/ml after 6 months of treatment (50.7% decrease, p < 0.01). The mean percent free PSA (21% to 22% at baseline) was not significantly altered by CMA treatment. The PSA levels and PV at baseline did not affect the rate of decline of PSA. Conclusions: The total PSA serum levels decreased by an average of 50% during CMA therapy, but the percent free PSA did not change significantly. This information is potentially useful in the interpretation of the PSA data that's used for early detection of prostate cancer in the men receiving CMA.

UR - http://www.scopus.com/inward/record.url?scp=33745613505&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745613505&partnerID=8YFLogxK

U2 - 10.4111/kju.2006.47.4.368

DO - 10.4111/kju.2006.47.4.368

M3 - Article

VL - 47

SP - 368

EP - 371

JO - Korean Journal of Urology

JF - Korean Journal of Urology

SN - 2005-6737

IS - 4

ER -